UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Lymphoid Leukemia · Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Colorado Hospital, Aurora, Colorado, United States
Contact: Study coordinator (Derek Schatz) · DEREK.SCHATZ@CUANSCHUTZ.EDU · 720-848-0628
Contact: Study coordinator (Andrew Roth, PhD) · andrew.g.roth@cuanschutz.edu
Contact: Principal Investigator (Mathew Angelos, MD)

Study leads

Mathew Angelos, MD
Principal Investigator
University of Colorado, Denver

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Leukemia · Acute Myeloid Leukemia in Remission · Myelodysplasia

Abroad (travel likely)Recruiting

Milwaukee, United States

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

B-cell Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia, in Relapse · Refractory Acute Lymphoid Leukemia

Abroad (travel likely)Recruiting

Beijing, China

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China